Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
RCKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.19 - $18.89
Previous CloseN/A
Volume339.48K
Average Volume (3M)2.36M
Market Cap
$338.82M
Enterprise Value$25.71M
Total Cash (Recent Filing)$271.49M
Total Debt (Recent Filing)$25.20M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 06, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding107,903,870
10 Day Avg. Volume2,538,671
30 Day Avg. Volume2,361,823
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.08
Enterprise Value/Revenue2.80
Enterprise Value/Gross Profit-7.73
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$9.00Price Target Upside165.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Bulls Say, Bears Say
Bulls Say
Cost ManagementRocket reiterated efforts to streamline the organization with the goal of reducing operating expenses by approximately 25%.
Regulatory MilestonesThe FDA lifted the clinical hold on the pivotal Ph2 study of RP-A501 in Danon disease, which is a meaningful positive for the stock.
Strategic InitiativesThe company's renewed strategic and financial focus on the AAV cardiovascular platform is seen as a potential driver for re-rating.
Bears Say
Asset WithdrawalRocket disclosed it has withdrawn its BLA application for RP-L102 in Fanconi anemia.
Clinical UncertaintyThere is a lack of near-term value drivers and remaining uncertainty around the company's main clinical program in Danon disease.
Development SetbacksThe company has become a 'show-me' story due to internal setbacks and broader disappointments in the gene-therapy space.
Rocket Pharmaceuticals News
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $2.19 and its highest was $18.89 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Rocket Pharmaceuticals’s market cap is $338.82M.
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 28 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.548 by -$0.072.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -0.49.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 107,903,870 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.548. Following the earnings report the stock price went down -7.443%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Currently, no hedge funds are holding shares in RCKT
Rocket Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (165.49% Upside)
$9.00 (165.49% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $41.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.34%
12-Months-Change
Fundamentals
Return on Equity
-69.65%
Trailing 12-Months
Asset Growth
-5.70%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. (RCKT) is a clinical-stage biotechnology company focused on developing first-in-class gene therapies for rare and devastating diseases. The company operates in the pharmaceutical sector, primarily targeting inherited genetic disorders with high unmet medical needs. Rocket Pharmaceuticals leverages its proprietary lentiviral vector platform to develop gene therapies aimed at providing long-lasting and potentially curative treatments for patients.
RCKT Stock 12 Month Forecast
Average Price Target
$9.00
▲(165.49% Upside)
Technical Analysis
Assembly Biosciences
―
CytomX Therapeutics
―
Autolus Therapeutics
―
4D Molecular Therapeutics
―
Alpha Tau Medical Ltd
―
Ownership Overview
19.45% Insiders
19.75% Mutual Funds
0.19% Other Institutional Investors
49.32% Public Companies and Individual Investors